Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49%

Alnylam Pharmaceuticals has seen a sharp reset in its share price over the past year, which puts fresh focus on what investors are actually paying for its earnings story today. After a stretch of mixed share returns over different time frames, the central issue is whether the current valuation lines up with the profits the business can generate.

• The stock is down 49.3% over the past year, which puts real pressure on the case that its current earnings power can support the latest price.
• The company continues to lean heavily on expectations for future profitability and cash generation from its drug portfolio, so the timing and durability of those earnings streams can materially influence what looks reasonable to pay for the shares today.
• The analysts covering Alnylam Pharmaceuticals have run their own numbers. See what analysts think Alnylam Pharmaceuticals's shares could be worth.

For investors, the debate is whether Alnylam Pharmaceuticals' current share price is appropriately aligned with what its earnings justify.

If you are questioning whether Alnylam Pharmaceuticals' earnings justify its latest move, it can help to compare that same test across 28 high quality undervalued stocks.

Has Alnylam Pharmaceuticals Run Too Far on Earnings?

The P/E ratio suits Alnylam Pharmaceuticals because investors are focused on how quickly its earnings can catch up to an already established market value. On this metric, the stock trades at about 39.9x earnings, which is higher than the Biotechs industry average of roughly 17.1x and also above the peer group on about 33.8x. That indicates the market is currently willing to pay more for each dollar of Alnylam Pharmaceuticals' profit than for many similar businesses.

The Fair Ratio model, which blends in factors such as expected growth, margins, risk profile and size for Alnylam Pharmaceuticals, points to a lower multiple than the one investors are paying today. Because the actual P/E sits above that tailored benchmark, the shares screen as overvalued on this specific earnings yardstick. The key question is whether the future profit path can ultimately support that richer P/E or whether the market is attaching too much weight to what the pipeline might deliver. Explore the numbers behind Alnylam Pharmaceuticals's P/E valuation.

The Alnylam Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Alnylam Pharmaceuticals act as the missing link between the rich P/E debate and the assumptions that would need to hold on growth, margins and earnings for the stock to be worth materially more or materially less than it is today. Each narrative anchors a fair value estimate to a specific storyline about Alnylam Pharmaceuticals' potential catalysts and key risks so you can track over time which version of events is actually unfolding on the Community page.

One of the top community narratives on Alnylam Pharmaceuticals: 38% undervalued

"The broad RNAi portfolio at Alnylam Pharmaceuticals, with more than 25 programs and multiple pivotal studies underway, creates repeated opportunities..."

Discover why this Narrative puts Alnylam Pharmaceuticals at 38% undervalued.

One more Alnylam Pharmaceuticals check that belongs beside the valuation math

The price tag is only part of the story, because the people steering Alnylam Pharmaceuticals and the way they are rewarded can sharply shape how this business is run over time. See who runs Alnylam Pharmaceuticals and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com